Study type

Study topic

Disease /health condition
Human medicinal product

Study type

Non-interventional study

Scope of the study

Drug utilisation

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Other

Non-interventional study design, other

Retrospective database study
Study drug and medical condition

Name of medicine

ZONEGRAN

Medical condition to be studied

Epilepsy
Population studied

Short description of the study population

The study participants included children and adolescents aged 6-18 years who had at least one prescription for zonisamide from 2013 to 2016, using the Clinical Practice Research Datalink GOLD database.

Age groups

Children (2 to < 12 years)
Adolescents (12 to < 18 years)

Special population of interest

Other

Special population of interest, other

Epilepsy patients

Estimated number of subjects

500
Study design details

Main study objective

To provide information as to whether recommendations in the product information are being adhered to with regard to the paediatric population and in order to provide evidence of the effectiveness of the routine risk minimisation measures through a retrospective database study

Data analysis plan

This study will utilise descriptive methods to summarise the key outcomes used to evaluate clinical care and prescribing for children taking Zonisamide. Descriptive summaries will be provided for all paediatric patients who have at least one prescription of Zonisamide, and then further stratified into groups A, B and C, depending on the presence of an epilepsy diagnosis within the patient’s medical record. No comparisons will be made between such groups, nor will any formal comparison testing be undertaken. Additionally as this is a descriptive drug utilisation study, no testing of statistical hypotheses, statistical modelling or other multivariate analyses will be performed.
Documents
Study results
English (86.24 KB - PDF)View document